摘要
Objective:Coronavirus disease 2019(COVID-19)is a global public health crisis.There are no specific antiviral agents for the treatment of SARS-CoV-2.Information regarding the effect of Abidol on in-hospital mortality is scarce.The present study aimed to evaluate the treatment effect of Abidol for patients with COVID-19 before and after propensity score matching(PSM).Methods:This retrospective cohort study analyzed 1019 patients with confirmed COVID-19 in China from December 22,2019 to March 13,2020.Patients were divided to Abidol(200mg,tid,5-7days,n=788,77.3%)and No-Abidol(n=231,22.7%)groups.The primary outcome was the mortality during hospitalization.Results:Among 1019 COVID-19 patients,the age was(60.4±14.5)years.Abidol-treated patients,compared with No-Abidoltreated patients,had a shorter duration from onset of symptoms to admission,less frequent renal dysfunction,lower white blood cell counts(lymphocytes<0.8)and erythrocyte sending rate,lower interleukin-6,higher platelet counts and plasma IgG and oxygen saturation,and less frequent myocardial injury.The mortality during hospitalization before PSM was 17.9% in Abidol group and 34.6% in No-Abidol(hazard ratio(HR)=2.610,95% confident interval(CI):1.980–3.440),all seen in severe and critical patients.After PSM,the in-hospital death was 13.6% in Abidol and 28.6% in No-Abidol group(HR=2.728,95%CI:1.598–4.659).Conclusions:Abidol-treatment results in less in-hospital death for severe and critical patients with COVID-19.Further randomized study is warranted to confirm the findings from this study.
